These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 11283121)

  • 61. Second-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly?
    Ota T; Takeshima N; Takizawa K
    Eur J Gynaecol Oncol; 2011; 32(5):471-5. PubMed ID: 22053655
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas.
    Matsuo K; Eno ML; Im DD; Rosenshein NB
    Arch Gynecol Obstet; 2010 Feb; 281(2):325-8. PubMed ID: 19455347
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.
    Reyners AKL; de Munck L; Erdkamp FLG; Smit WM; Hoekman K; Lalisang RI; de Graaf H; Wymenga ANM; Polee M; Hollema H; van Vugt MATM; Schaapveld M; Willemse PHB;
    Ann Oncol; 2012 Nov; 23(11):2896-2902. PubMed ID: 22689176
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
    Teneriello MG; Tseng PC; Crozier M; Encarnacion C; Hancock K; Messing MJ; Boehm KA; Williams A; Asmar L
    J Clin Oncol; 2009 Mar; 27(9):1426-31. PubMed ID: 19224848
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.
    Neijt JP; Engelholm SA; Tuxen MK; Sorensen PG; Hansen M; Sessa C; de Swart CA; Hirsch FR; Lund B; van Houwelingen HC
    J Clin Oncol; 2000 Sep; 18(17):3084-92. PubMed ID: 10963636
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
    Huizing MT; van Warmerdam LJ; Rosing H; Schaefers MC; Lai A; Helmerhorst TJ; Veenhof CH; Birkhofer MJ; Rodenhuis S; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1997 May; 15(5):1953-64. PubMed ID: 9164207
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
    Herzog TJ; Monk BJ; Rose PG; Braly P; Hines JF; Bell MC; Wenham RM; Secord AA; Roman LD; Einstein MH; Drake RD; Childs BH
    Gynecol Oncol; 2014 Mar; 132(3):517-25. PubMed ID: 24476788
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study.
    Rose PG; Blessing JA; Ball HG; Hoffman J; Warshal D; DeGeest K; Moore DH
    Gynecol Oncol; 2003 Feb; 88(2):130-5. PubMed ID: 12586591
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer.
    Seliger G; Mueller LP; Kegel T; Kantelhardt EJ; Grothey A; Groe R; Strauss HG; Koelbl H; Thomssen C; Schmoll HJ
    Int J Gynecol Cancer; 2009 Nov; 19(8):1446-53. PubMed ID: 20009905
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.
    Coleman RL; Duska LR; Ramirez PT; Heymach JV; Kamat AA; Modesitt SC; Schmeler KM; Iyer RB; Garcia ME; Miller DL; Jackson EF; Ng CS; Kundra V; Jaffe R; Sood AK
    Lancet Oncol; 2011 Nov; 12(12):1109-17. PubMed ID: 21992853
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dose-dense approaches to ovarian cancer treatment.
    Katsumata N
    Curr Treat Options Oncol; 2015 May; 16(5):21. PubMed ID: 25859831
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial.
    Kushner DM; Connor JP; Sanchez F; Volk M; Schink JC; Bailey HH; Harris LS; Stewart SL; Fine J; Hartenbach EM;
    Gynecol Oncol; 2007 May; 105(2):358-64. PubMed ID: 17258800
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
    Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
    Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of Prophylactic Extended-Infusion Carboplatin on Incidence of Hypersensitivity Reactions in Patients with Ovarian, Fallopian Tube, or Peritoneal Carcinomas.
    Pasternak AL; Link NA; Richardson CM; Rose PG
    Pharmacotherapy; 2016 Jul; 36(7):723-30. PubMed ID: 27196693
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer.
    Schmeler KM; Vadhan-Raj S; Ramirez PT; Apte SM; Cohen L; Bassett RL; Iyer RB; Wolf JK; Levenback CL; Gershenson DM; Freedman RS
    Gynecol Oncol; 2009 May; 113(2):210-5. PubMed ID: 19264351
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Thrombocytopenia associated with second-line carboplatin-based chemotherapy for ovarian, fallopian tube, and primary peritoneal cavity cancers.
    Markman M; Markman J; Webster K; Zanotti K; Kulp B; Peterson G; Belinson J
    J Cancer Res Clin Oncol; 2004 Dec; 130(12):741-4. PubMed ID: 15338296
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A phase I study of carboplatin and docetaxel for advanced non-small cell lung cancer using the continual reassessment method.
    Kasahara K; Myo S; Iwasa K; Kimura H; Shirasaki H; Yasuda U; Shibata K; Shintani H; Nishi K; Fujimura M; Nakao S
    Jpn J Clin Oncol; 2002 Dec; 32(12):512-6. PubMed ID: 12578899
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.
    Rose PG; Fusco N; Fluellen L; Rodriguez M
    J Clin Oncol; 1998 Apr; 16(4):1494-7. PubMed ID: 9552057
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer.
    Mori T; Hosokawa K; Kinoshita Y; Watanabe A; Yamaguchi T; Kuroboshi H; Kato Y; Yasuda J; Fujita H; Nakata Y; Honjo H
    Int J Clin Oncol; 2007 Jun; 12(3):205-11. PubMed ID: 17566844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.